4 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Withdrawn 4 |
Follow Peripheral Nervous System Neoplasms: new trials by email Literature Review of Peripheral Nervous System Neoplasms trials Research Report on Peripheral Nervous System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, Phaseâ…¡, Double-Blinded, Placebo-Controlled Study Selumetinib, Placebo - Neurofibromatosis Type 1, Plexiform Neurofibromas | Phase 2 | Withdrawn | AstraZeneca | 2023-08-31 | 2023-08-14 | |
| Study of Imatinib in Children With Neurofibromatosis and Airway Tumors Imatinib Mesylate - Neurofibroma, Plexiform | Phase 2 | Withdrawn | Indiana University | 2018-09-01 | 2021-02-12 | |
| Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors CPI-0610 - Peripheral Nerve Tumors | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2017-05-05 | 2018-09-11 | |
| Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) Selumetinib (AZD6244 hyd sulfate) 50mg/dose, Selumetinib (AZD6244 hyd sulfate) 25mg/m2 - Neoplasms, Nerve Tissue, Neurofibromatosis 1 | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2017-04-07 | 2019-04-05 |
Neurofibroma, Plexiform (3) · Neurofibromatosis 1 (2) · Heredodegenerative Disorders, Nervous System (1) · Neoplasms, Nerve Tissue (1) · Neurofibrosarcoma (1) · Peripheral Nervous System Diseases (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Nerve Sheath Neoplasms (4) · Nervous System Diseases (4) · Nervous System Neoplasms (4) · Neurofibroma (4) · Neuromuscular Diseases (4) · Neoplasms, Nerve Tissue (3) · Peripheral Nervous System Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Neoplastic Syndromes, Hereditary (2) · Neurocutaneous Syndromes (2) · Neurodegenerative Diseases (2)
AZD 6244 (2) · CPI-0610 (1) · Imatinib Mesylate (1)
AstraZeneca (1) · Indiana University (1) · National Cancer Institute (NCI) (1) · University of Texas Southwestern Medical Center (1)
United States (2)
Brigitte C Widemann, M.D. (1) · Xin Ni (1)